🇺🇸 Red Blood Cell Transfusion in United States

38 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 38

Most-reported reactions

1. Platelet Count Decreased — 6 reports (15.79%)
2. Febrile Neutropenia — 5 reports (13.16%)
3. Pneumonia — 4 reports (10.53%)
4. Sickle Cell Anaemia With Crisis — 4 reports (10.53%)
5. Thrombocytopenia — 4 reports (10.53%)
6. Anaemia — 3 reports (7.89%)
7. Atrial Fibrillation — 3 reports (7.89%)
8. Myelodysplastic Syndrome — 3 reports (7.89%)
9. Oedema Peripheral — 3 reports (7.89%)
10. Off Label Use — 3 reports (7.89%)

Source database →

Frequently asked questions

Is Red Blood Cell Transfusion approved in United States?

Red Blood Cell Transfusion does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Red Blood Cell Transfusion in United States?

Rutgers, The State University of New Jersey is the originator. The local marketing authorisation holder may differ — check the official source linked above.